Plain-English translation of NCT07314684 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing , a medication that helps control blood sugar in type 2 diabetes, to see if it also protects your heart and reduces harmful inflammation in your body. Right now, doctors know this medication is helpful for people with diabetes who already have heart problems, but there's not enough evidence about how it works to prevent heart disease in people who don't have it yet. This study will measure changes in your heart health and blood markers over one year.
Type 2 diabetes significantly increases the risk of heart disease and heart attacks over time. This medication is already recommended for people with existing heart problems, but doctors want to understand whether it can also help prevent heart disease in people who are at risk but don't have it yet—and exactly how it protects the heart.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either take the medication in addition to your current diabetes treatment or continue with your current treatment alone. Over 52 weeks (one year), you will visit the clinic three times: at the start, at 26 weeks, and at 52 weeks. At each visit, you'll have blood tests, an EKG (heart rhythm test), an ultrasound of your heart, and routine check-ups to measure how the treatment is affecting your heart health and inflammation levels.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Italy